Skip to main content
SpringerLink
Log in

Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Tenth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on September 22 and 23, 2017. This scientific program was developed by clinicians for clinicians and was promoted by two major clinical research institutes—the Brazilian Clinical Research Institute and the Duke Clinical Research Institute of the Duke University School of Medicine. Comprising academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. van Es N, Di Nisio M, Bleker SM et al (2015) Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 114:1268–1276

    Article  PubMed  Google Scholar 

  2. Young A, Phillips J, Hancocks H et al (2016) OC-11 -anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 140(Suppl 1):S172–S173

    Article  PubMed  Google Scholar 

  3. Khorana AA, Carrier M, Garcia DA, Lee AY (2016) Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 41:81–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 149:315–352

    Article  PubMed  Google Scholar 

  5. Francis CW, Kessler CM, Goldhaber SZ et al (2015) Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 13:1028–1035

    Article  CAS  PubMed  Google Scholar 

  6. Chai-Adisaksopha C, Iorio A, Crowther MA et al. (2017) Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism. Am J Med. https://doi.org/10.1016/j.amjmed.2017.11.042. (Epub ahead of print)

    PubMed  Google Scholar 

  7. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW (2016) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 12:Cd008500

    PubMed  Google Scholar 

  8. Khorana AA, Vadhan-Raj S, Kuderer NM et al (2017) Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost 117:2135–2145

    Article  PubMed  Google Scholar 

  9. U.S. National Library of Medicine, ClinicalTrials.gov (2017) Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://www.clinicaltrials.gov/ct2/show/NCT02048865. Accessed 5 Feb 2018

  10. van der Hulle T, den Exter PL, Planquette B et al (2016) Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 14:105–113

    Article  PubMed  Google Scholar 

  11. O’Connell C, Razavi P, Ghalichi M et al (2011) Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 9:305–311

    Article  PubMed  Google Scholar 

  12. Di Nisio M, Lee AY, Carrier M, Liebman HA, Khorana AA (2015) Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 13:880–883

    Article  PubMed  Google Scholar 

  13. Kuramatsu JB, Gerner ST, Schellinger PD et al (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313:824–836

    Article  CAS  PubMed  Google Scholar 

  14. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY (2015) Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 32:517–525

    Article  Google Scholar 

  15. Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15:244–252

    PubMed  Google Scholar 

  16. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  17. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  18. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  19. Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104

    Article  CAS  PubMed  Google Scholar 

  20. Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962

    Article  CAS  PubMed  Google Scholar 

  21. Pokorney SD, Simon DN, Thomas L et al (2016) Stability of international normalized ratios in patients taking long-term warfarin therapy. JAMA 316:661–663

    Article  PubMed  Google Scholar 

  22. Guimaraes PO, Kaatz S, Lopes RD (2015) Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. Int J Gen Med 8:283–291

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330

    Article  CAS  PubMed  Google Scholar 

  24. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126:1630–1639

    Article  CAS  PubMed  Google Scholar 

  25. Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e326S–e350S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Clark NP, Witt DM, Davies LE et al (2015) Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med 175:1163–1168

    Article  PubMed  Google Scholar 

  27. Doherty JU, Gluckman TJ, Hucker WJ et al (2017) 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American college of cardiology clinical expert consensus document task force. J Am Coll Cardiol 69:871–898

    Article  PubMed  Google Scholar 

  28. Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962

    Article  PubMed  Google Scholar 

  29. January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:e1–e76

    Article  PubMed  Google Scholar 

  30. Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P (2014) Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 70:1477–1485

    Article  CAS  PubMed  Google Scholar 

  31. Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125:2298–2307

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Duke University School of Medicine, Box 3850, 2400 Pratt Street, Durham, NC, 27705, USA

    Renato D. Lopes & Patricia O. Guimarães

  2. Department of Medicine, McMaster University, Hamilton, ON, Canada

    Mark Crowther

  3. Boston University Medical Center, Boston, MA, USA

    Elaine Hylek

  4. Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, BA, Brazil

    Gilson S. Feitosa-Filho & Luiz E. Ritt

  5. Hospital Santa Izabel - Santa Casa da Bahia, Salvador, BA, Brazil

    Gilson S. Feitosa-Filho

  6. Hospital Ana Nery, Salvador, BA, Brazil

    Gilson S. Feitosa-Filho

  7. Hospital Cárdio Pulmonar, Salvador, BA, Brazil

    Luiz E. Ritt

  8. Universidade Salvador (UNIFACS) - rede Laureate, Salvador, BA, Brazil

    Nivaldo Filgueiras

  9. Universidade do Estado da Bahia (UNEB), Salvador, BA, Brazil

    Nivaldo Filgueiras

  10. Fundação Bahiana de Cardiologia, Salvador, BA, Brazil

    Nivaldo Filgueiras

  11. Hospital da Cidade, Salvador, BA, Brazil

    Nivaldo Filgueiras

  12. Department of Medicine, University of Washington Medical Center, University of Washington School of Medicine, Seattle, WA, USA

    David A. Garcia

Authors
  1. Renato D. Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia O. Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Crowther
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elaine Hylek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gilson S. Feitosa-Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luiz E. Ritt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nivaldo Filgueiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David A. Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renato D. Lopes.

Ethics declarations

Conflict of interest

RDL has received research grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer; and consulting fees from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola Pharmaceutical. POG declares that she has no conflict of interest. MC has served on a DSMB for Bayer, Daiichi; provided consulting for Octapharma, BMS Canada; received research support from Bayer, Pfizer, Heart and Stroke Foundation; and reports stock ownership in Alnylam. EH has served as a consultant or on an advisory board for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Armetheon Daiichi Sankyo, Janssen, Medtronic Pfizer, and Portola. GSF-F, LER, and NF declare that they have no conflicts of interest. DAG has received research grants from Incyte, Janssen, and Daiichi Sankyo; and consulting fees from Incyte, Alexion, Janssen, Pfizer, Bristol-Myers Squibb, and Boehringer-Ingelheim.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopes, R.D., Guimarães, P.O., Crowther, M. et al. Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. J Thromb Thrombolysis 45, 578–587 (2018). https://doi.org/10.1007/s11239-018-1639-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-018-1639-9

Keywords

Search

Navigation